Valeant considering sale of eye-surgery assets — Carl Zeiss interest rumored

Bloomberg reports Valeant Pharmaceuticals is considering selling its Bausch & Lomb surgical products to Carl Zeiss Meditec.

Advertisement

Here’s what you should know:

1. Analysts believe Bausch & Lomb is worth $2 billion.

2. Anonymous sources told Bloomberg talks are ongoing with an agreement “still weeks away.”

3. Valeant could consider other bidders.

4. Valeant has $28.9 billion in debt. CEO Joe Papa is working to stabilize the company after it suffered from government pricing probes coupled with poor sales.

More articles on improving health:
ASCA Healthcare Asset Network to create online shopping portal: 4 features
10 states where the most people delay necessary medical care
20 latest notes on hourly, annual wages for ASC nurses, tech & administrative staff

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in ASC News

  • Atlanta-based United Digestive is planning an ASC in Watkinsville, Ga., focusing on organic growth to expand its network. The newly-constructed,…

  • At least 25 ASCs have closed over the past five years, a pattern of attrition driven by financial strain, staffing…

  • As the ASC industry continues to grow alongside new waves of surgical innovation, patient preferences and shifts to value-based care,…

Advertisement

Comments are closed.